Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

NCT06663137 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Muscle Invasive Bladder Cancer

Interventions

DRUG: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

Sponsor

Relmada Therapeutics, Inc.